| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/09/2002 | CN1330640A Cyclic hydrazine derivatives as TNF-alpha inhibitors |
| 01/09/2002 | CN1330630A 7-aryl-6(z) heptantriene acid vitamin A amide as apoptosis inducing compounds and their use as anti-cancer agents |
| 01/09/2002 | CN1330557A In situ injection of antigen-presenting cells with generatically enhanced cytokine expression cell factor |
| 01/09/2002 | CN1330555A Antibodies to truncated VEGF-D and uses thereof |
| 01/09/2002 | CN1330554A Chimeric anti-CD20 antibody treatment of paitients receiving BMT or PBSC transplants |
| 01/09/2002 | CN1330553A Adjuvant systems and vaccines |
| 01/09/2002 | CN1330551A Pharmaceutical formulation of Didemnin compound |
| 01/09/2002 | CN1330545A Treating for skin disease |
| 01/09/2002 | CN1330532A Oil-in-water emulsion comprising micronised biologically active agent and appropriate emulsified system |
| 01/09/2002 | CN1330148A Newcastle disease virus HN and chick anemia virus VP3 gene joined antineoplastic biologic preparation |
| 01/09/2002 | CN1330147A Polypeptide-human alpha 2,3-sialyltransferase (ST3 GalVI) 9.57 and polynucleotide for coding it |
| 01/09/2002 | CN1330144A Polypeptide-human class-I aminoacyl-tRNA synthetase 10 and polynucleotide for coding it |
| 01/09/2002 | CN1330073A Peptide nucleic acid derivatives, intermediate for preparing them and medicinal composition containing them |
| 01/09/2002 | CN1329921A Orally applied medicine containing Nostoc which expressing human tumor necrosin factor alpha |
| 01/09/2002 | CN1329920A Process for preparing medicine composition containing glutacthion or its salt |
| 01/09/2002 | CN1329918A Prescription and preparing process for anticancer medicine |
| 01/09/2002 | CN1329909A Anticancer composite medicine |
| 01/09/2002 | CN1329904A Process for preparing arnebia root medicine with broad-spectrum medical functions |
| 01/09/2002 | CN1329891A Vascular formation inhibitor |
| 01/09/2002 | CN1329885A Preparing process and application of clam lipoid |
| 01/09/2002 | CN1077575C Camptothecin derivatives and their manufacturing method and its intermediate |
| 01/09/2002 | CN1077572C 取代的吡咯 Substituted pyrrole |
| 01/09/2002 | CN1077571C Substituted bisindolylmaleimides for inhibition of cell proliferation |
| 01/09/2002 | CN1077440C Radioactive rhenium marking tin-sulphur colloid agent, prepn. method and use therefor |
| 01/09/2002 | CN1077409C Preparation process of insects protein powder |
| 01/08/2002 | US6337411 Muscular disorders |
| 01/08/2002 | US6337348 Inhibiting motility of sperm with oxovanadium compound with 1,10-phenanthroline, 2,2'bipyridine, 2'hydroxyacetophenone or 3-hydroxypropenal for complexes |
| 01/08/2002 | US6337346 Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents |
| 01/08/2002 | US6337342 Bis-aryl or heteroaryl indoles |
| 01/08/2002 | US6337338 Heteroaryl-aryl ureas as IGF-1 receptor antagonists |
| 01/08/2002 | US6337335 Enzyme inhibitors for autoimmune diseases, transplant rejection, grant versus host disease, hyperproliferative disorders and diseases in which cells receive pro-inflammatory signals. |
| 01/08/2002 | US6337318 Drugs for peptide agonist |
| 01/08/2002 | US6337209 Molecular constructs containing a carcinoembryonic antigen regulatory sequence |
| 01/08/2002 | US6337187 An isolated nucleic acid molecule; diagnosis and therapy for obesity, hypertriglyceridemia, and atherosclerosis |
| 01/08/2002 | CA2143263C Orally administrable raloxifene formulations |
| 01/08/2002 | CA2051356C Antineoplastic modified imidazoacridines |
| 01/08/2002 | CA2019559C Bispecific and oligospecific mono- and oligovalent receptors, the preparation and use thereof |
| 01/03/2002 | WO2002000906A2 Replication deficient adenoviral tnf vector |
| 01/03/2002 | WO2002000894A2 Gene silencing vector |
| 01/03/2002 | WO2002000892A1 Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest |
| 01/03/2002 | WO2002000887A1 Novel therapeutic molecular variants and uses thereof |
| 01/03/2002 | WO2002000877A2 Antisense oligonucleotides to inhibit angiogenesis and/or metastasis |
| 01/03/2002 | WO2002000876A1 Truncated egf receptor |
| 01/03/2002 | WO2002000867A1 Prostase protein vaccine comprising derivatised thiol residues and methods for producing said antigen |
| 01/03/2002 | WO2002000866A1 A new polypeptide- human i class aminoacyl-trna synthetase 10 and the polynucleotide encoding it |
| 01/03/2002 | WO2002000860A2 Novel proteases |
| 01/03/2002 | WO2002000840A2 Human lyases |
| 01/03/2002 | WO2002000827A2 A novel polypeptide, a dna-cysteine methyltransferase methylation protein 10 and the polynucleotide encoding the polypeptide |
| 01/03/2002 | WO2002000825A2 A novel polypeptide, a nuclear receptor protein stromal antigene 110.34 and the polynucleotide encoding the polypeptide |
| 01/03/2002 | WO2002000821A2 A novel polypeptide, a human protein plp39 and the polynucleotide encoding the polypeptide |
| 01/03/2002 | WO2002000734A1 Dds compound and process for the preparation thereof |
| 01/03/2002 | WO2002000730A2 Pd-l2 molecules: novel pd-1 ligands and uses therefor |
| 01/03/2002 | WO2002000727A2 Gp286 nucleic acids and polypeptides |
| 01/03/2002 | WO2002000711A2 Ev-vegf nucleic acids and polypeptides and methods of use |
| 01/03/2002 | WO2002000692A2 Pd-l2 molecules: pd-1 ligands and uses therefor |
| 01/03/2002 | WO2002000691A2 Polynucleotides and polypeptides encoded thereby |
| 01/03/2002 | WO2002000690A2 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/03/2002 | WO2002000680A2 Cationic steroid derivatives for gene delivery |
| 01/03/2002 | WO2002000663A2 Polycyclic xanthones as antibiotics |
| 01/03/2002 | WO2002000662A1 Improvements in and relating to chromophores |
| 01/03/2002 | WO2002000661A1 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS |
| 01/03/2002 | WO2002000658A1 Cyclic gmp-specific phosphodiesterase inhibitors |
| 01/03/2002 | WO2002000656A2 Pirazino '1$m(1)2$m(1) :1, 6! pyrido '3,4-b! indole derivatives |
| 01/03/2002 | WO2002000653A2 Fused cyclic compounds as modulators of nuclear hormone receptor function |
| 01/03/2002 | WO2002000650A2 Novel compounds possessing antibacterial, antifungal or antitumor activity |
| 01/03/2002 | WO2002000649A1 Substituted quinazoline derivatives and their use as inhibitors |
| 01/03/2002 | WO2002000632A1 Benzodiazepines as inhibitors of hpv e1 helicase |
| 01/03/2002 | WO2002000630A1 Polymorphic forms/hydrates of n-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)-quinazolin-6-yl]-acrylamide dihydrochloride |
| 01/03/2002 | WO2002000624A2 Methods and compounds for inhibiting mrp1 |
| 01/03/2002 | WO2002000621A1 Compounds exhibiting x-type spla2 inhibiting effect |
| 01/03/2002 | WO2002000617A2 Selective androgen receptor modulators and methods for their identification, design and use |
| 01/03/2002 | WO2002000611A2 Fmoc-l-leucine and derivatives thereof as ppar-gamma agonists |
| 01/03/2002 | WO2002000263A2 Tripeptide prodrug compounds |
| 01/03/2002 | WO2002000262A2 Modulation of chromosome function by chromatin remodeling agents |
| 01/03/2002 | WO2002000255A1 Remedies for cancer |
| 01/03/2002 | WO2002000243A2 Stabilized interleukin 2 |
| 01/03/2002 | WO2002000242A2 Human papilloma virus treatment |
| 01/03/2002 | WO2002000237A1 Therapeutical use of sophora flavescens or sophora subprostrata extracts |
| 01/03/2002 | WO2002000236A1 Extracts from sophora species, method for producing the same and their use |
| 01/03/2002 | WO2002000233A2 Purging of cells using viruses |
| 01/03/2002 | WO2002000227A2 Use of lanthanum compounds for the treatment of bone diseases |
| 01/03/2002 | WO2002000223A1 Use of potassium channel agonists for reducing fat food comsumption |
| 01/03/2002 | WO2002000222A1 Use of potassium channel agonists for the treatment of cancer |
| 01/03/2002 | WO2002000217A1 Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators |
| 01/03/2002 | WO2002000194A2 Polymeric micelle compositions |
| 01/03/2002 | WO2002000192A2 Embolization using carbon coated particles |
| 01/03/2002 | WO2002000174A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/03/2002 | WO2002000172A2 Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| 01/03/2002 | WO2002000170A2 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer |
| 01/03/2002 | WO2002000167A2 Modified forms of pharmacologically active agents and uses therefor |
| 01/03/2002 | WO2002000017A2 Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5 |
| 01/03/2002 | WO2002000001A2 HUMAN G PROTEIN-COUPLED RECEPTOR IGPcR20, AND USES THEREOF |
| 01/03/2002 | WO2001071005A3 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 01/03/2002 | WO2001070693A3 Difluorobutyric acid derivatives and their use as metalloprotease inhibitors |
| 01/03/2002 | WO2001070275A3 Polyglutamic acid-camptothecin conjugates and methods of preparation |
| 01/03/2002 | WO2001066601A8 Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals |
| 01/03/2002 | WO2001055336A3 Methods and materials relating to cd84-like polypeptides and polynucleotides |
| 01/03/2002 | WO2001053344A3 Chondromodulin-i related peptide |
| 01/03/2002 | WO2001051473A8 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation |
| 01/03/2002 | WO2001049713A3 Stabilizing peptides, polypeptides and antibodies which include them |